Cargando…
Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
Primary debulking surgery (PDS) has remained the only treatment of ovarian cancer with survival advantage since its development in the 1970s. However, survival advantage is only observed in patients who are optimally resected. Neoadjuvant chemotherapy (NACT) has emerged as an alternative for patient...
Autores principales: | Cummings, Mackenzie, Nicolais, Olivia, Shahin, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026414/ https://www.ncbi.nlm.nih.gov/pubmed/35454036 http://dx.doi.org/10.3390/diagnostics12040988 |
Ejemplares similares
-
Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
por: McNamara, Blair, et al.
Publicado: (2021) -
An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer
por: Finch, Lindsey, et al.
Publicado: (2023) -
Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020) -
Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis
por: Bartels, Helena C., et al.
Publicado: (2019) -
A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
por: Ahmad, Sheikh Zahoor, et al.
Publicado: (2015)